Highest-materiality recent filing
Sana Biotechnology stockholders elect three Class II directors; ratify EY as auditor
Hans E. Bishop elected with 117,452,573 For vs 57,148,432 Withheld; 30,606,441 broker non-votes.
Sana Biotechnology sells 21.6M shares for $69M in at-the-market offering
Sold 21,607,878 shares for net proceeds of approx. $69.0 million on May 15, 2026.
Sana Q1 net loss $47.2M, cash $101.1M; Mayo $25M equity; SC451/SG293 trials on track for 2026
Net loss of $47.2M ($0.17/sh); R&D expenses $28.7M (down from $37.2M YoY).
Director Steven D. Harr resigned as Class I director and was reappointed as Class III director effective April 22, 2026.
Sana Biotechnology sells $25M in stock to Mayo Clinic with option for additional $25M
Issued 7,507,507 shares at $3.33 each to Mayo Clinic for ~$25M gross proceeds; closing expected April 15, 2026.
UP421 hypoimmune islet cells in type 1 diabetes show C-peptide production, immune evasion at 1 year without immunosuppression.
Sana Biotechnology appoints Brian Piper as EVP, CFO; base salary $515K, option grant of 900K shares
Brian Piper appointed EVP, CFO and Treasurer effective February 17, 2026; replaces Steven Harr as acting principal financial officer.
Sana: UP421 survives 12 months in T1D with no immunosuppression; plans SC451 IND, SG293 data in 2026
UP421, a hypoimmune pancreatic islet cell therapy, continued to survive and function at 12 months post-transplant in a T1D patient with no immunosuppression.
Q3 net loss $42.2M ($0.16/share); cash $153.1M; raised $115.8M in Q3, pro forma cash $170.5M.
Sana Biotechnology GC Bernard Cassidy to retire Oct 20; Aaron Grossman named successor
Bernard Cassidy will retire as EVP, General Counsel, effective Oct 20, 2025.
Sana Biotechnology director Mary Agnes Wilderotter resigns effective Aug 29
Mary Agnes Wilderotter resigned as director and chair of Nominating and Corporate Governance Committee, effective Aug 29, 2025.
Sana Biotechnology Q2 loss $0.39/sh (GAAP); positive type 1 diabetes cell therapy data; raises $105M
Net loss $93.8M ($0.39/sh GAAP); non-GAAP net loss $38.9M ($0.16/sh) vs $74.2M ($0.32/sh) year ago.
Sana Biotechnology prices $75M public offering of common stock and pre-funded warrants
Priced 20,895,522 shares at $3.35/share and 1,492,537 pre-funded warrants at $3.3499/underlying share.
Sana reports $90.1M cash, $40-45M facility impairment; positive UP421 data at 6 months
Cash, cash equivalents and marketable securities ~$90.1M as of July 31, 2025.
Six-month results: transplanted allogeneic islet cells (UP421) safe, survive, evade immune system, produce insulin without immunosuppression.
Sana Biotechnology shareholders elect all four director nominees and ratify auditor
All four Class I directors elected: Steven D. Harr (147.9M for), Robert L. Rosiello (158.2M for), Michelle Seitz (147.9M for), Patrick Y. Yang (143.7M for).
Sana reports Q1 net loss $49.4M, cash runway into 2026; new $119M ATM facility
Net loss $49.4M ($0.21/share) vs $107.5M ($0.49/share) in Q1 2024; loss narrowed.
Sana reports Q4 net loss $49.1M; positive T1D islet cell data at 12 weeks
HIP-modified islet cells (UP421) produced C-peptide and MMTT response at 12 weeks without immunosuppression; no safety issues.
Sana Biotechnology furnishes JPM presentation; no new details in filing
Company presented updated corporate deck at 43rd Annual J.P. Morgan Healthcare Conference on Jan 13, 2025.
Sana Biotechnology Q3 2024 net loss $59.9M; advancing three clinical programs; cash runway into 2026
Net loss of $59.9M ($0.25/sh) for Q3 2024 vs net income of $1.0M in Q3 2023.
Sana Biotechnology CFO Nathan Hardy resigns; CEO Harr named acting PFO, Susan Wyrick acting CFO
CFO Nathan Hardy resigned effective Oct 4, 2024; acting appointments made same day.
CFO Nathan Hardy resigns effective October 4, 2024
Nathan Hardy notified resignation as EVP and CFO on September 6, 2024, effective October 4, 2024.
Sana Q2 net loss $50.3M ($0.21/sh); cash $251.6M; operating burn target <$200M
Net loss $50.3M ($0.21 per share), improved from $114M loss ($0.59) in Q2 2023.
Sana Biotechnology shareholders elect all three Class III directors and ratify EY as auditor
Joshua H. Bilenker, M.D. elected with ~149M votes for, ~16M withheld.
Sana Q1 net loss $107.5M; cash $311M after $189.8M financing; four trials on track for 2024
Net loss GAAP $107.5M ($0.49/share) vs $82.1M ($0.43) YoY; adjusted net loss $69.5M ($0.32).
Sana Biotechnology R&D President Douglas Williams resigns effective April 18, 2024
Douglas Williams, Ph.D., resigned as EVP and President, Research and Development.
Q4 2023 net loss $88.1M ($0.45/share); full year net loss $283.3M ($1.46/share).
Sana Biotechnology prices upsized $165M public offering of common stock and pre-funded warrants
Sold 17.3M shares at $5.50 and pre-funded warrants for 12.7M shares at $5.4999 each.
Sana reports SC291 ARDENT interim data with responses and immune evasion; cash $205.4M
Preliminary cash, cash equivalents and marketable securities as of Jan 2, 2024: approximately $205.4 million.
Sana presents corporate update at J.P. Morgan Healthcare Conference; details not in filing text
Corporate presentation furnished as Exhibit 99.1 for the 42nd Annual J.P. Morgan Healthcare Conference on Jan 9, 2024.
Filing references an updated corporate presentation as Exhibit 99.1, but no content from the deck is provided in the exhibit text.
Sana Biotechnology Q3 2023 GAAP net income $1.0M; cash $268.6M, pipeline data expected 2023-2024
Q3 2023 GAAP net income $1.0M driven by $82.6M gain from fair value changes on success payment liabilities.
Sana cuts workforce 29%, delays SG299 IND; 2024 cash burn under $200M
Workforce reduction of ~29%; expects 2024 operating cash burn below $200 million.
Sana expects to file investigational new drug application for SC291 in autoimmune diseases in Q4 2023.
Sana Biotechnology terminates Fremont lease for $3.42M; moves manufacturing to Bothell, WA
Lease for 163,193 sq ft in Fremont, CA terminated Aug 30, 2023.
Sana Q2 net loss $114M ($0.59/shr); cash $325.9M; SC291 enrollment ongoing, data expected H2 2023
Net loss of $114M in Q2 2023 vs $72.5M in Q2 2022; six-month net loss $196.1M.
Sana Biotechnology 2023 annual meeting results; all director nominees elected, auditor ratified
Hans E. Bishop elected Class II director with 108,928,064 votes for, 19,856,165 withheld.
Sana Biotechnology presents corporate update at Jefferies conference; no specific data in filing
Filed updated corporate presentation as Exhibit 99.1 for Jefferies Healthcare Conference on June 7, 2023.
Sana Biotechnology Q1 net loss $82.1M; advancing SC291 trial with data expected H2 2023
Cash $355.1M, supports operations into 2025; non-GAAP operating cash burn $74.8M for Q1.
Sana Biotechnology announces departure of Sunil Agarwal as EVP, Head of Development and CMO
Separation effective April 28, 2023; Sunil Agarwal to provide transition services under a Transition Agreement.
Douglas Williams, Ph.D., appointed EVP & President, R&D effective April 10, 2023; previously CEO of Codiak BioSciences.
Sana reports Q4 net loss $80.4M; cash $434M; SC291 IND cleared, expects clinical data this year
Net loss Q4 2022 $80.4M ($0.42/sh) vs $110.7M ($0.60/sh) in Q4 2021; FY2022 net loss $269.5M ($1.43/sh).
FDA clears Sana's IND for SC291 allogeneic CAR T therapy in B-cell malignancies
SC291 is a CD19-targeted allogeneic CAR T cell therapy using Sana's hypoimmune platform.
FDA cleared IND for SC291, a CD19-targeted allogeneic CAR T therapy using Sana's hypoimmune platform, in patients with B-cell lymphomas or leukemias.
Sana 8-K furnishes J.P. Morgan presentation; no material new data disclosed
Company presented updated corporate presentation at 41st Annual J.P. Morgan Healthcare Conference on Jan 10, 2023.
Sana Biotech prioritizes pipeline, cuts 15% staff, halts SC187; maintains cash runway into 2025
Headcount reduced by ~15%; expects ~$7.9M in cash severance and ~$2.2M non-cash stock-based comp charges.
Sana Biotechnology reports Q3 net loss $85.1M; cash $511.6M; pipeline IND timeline updates
Net loss of $85.1M ($0.45 per share) vs $83.3M ($0.46 per share) in Q3 2021; cash, cash equivalents and marketable securities $511.6M at Sep 30, 2022.
Board adopted amended Code on October 27, 2022, adding details on potential conflicts of interest.
Sana Q2 net loss $72.5M; cash runway extended into 2025 on manufacturing move savings
Cash position $579.6M at June 30, 2022, down $167.3M from Dec 31, 2021.
Sana Biotechnology presents updated corporate deck at Goldman Sachs conference
Company discussed updated corporate presentation at Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 2022.
Nathan Hardy’s resignation as Executive Vice President and Chief Financial Officer, Treasurer, Principal Financial Officer (“PFO”), and Principal Accounting Officer (“PAO”)
Susan Wyrick, the Company’s Senior Vice President, Finance and Accounting, was appointed to serve as Acting Chief Financial Officer, Treasurer, and PAO
Steven D. Harr, M.D., the Company’s President and Chief Executive Officer, was appointed to serve as acting PFO in addition to his role as President and Chief Executive Officer.
On September 6, 2024, Nathan Hardy notified Sana Biotechnology, Inc. (the “Company”) that he intends to resign from his position as Executive Vice President and Chief Financial Officer of the Company effective October 4, 2024.
Effective April 18, 2024, Douglas Williams, Ph.D. resigned from his position as Executive Vice President and President, Research and Development of Sana Biotechnology, Inc. (the “Company”).
Sana Biotechnology, Inc. (the “Company”) previously filed a Current Report on Form 8-K disclosing the resignation of Sunil Agarwal, M.D. as the Company’s Executive Vice President, Head of Development, and Chief Medical Officer.
Sunil Agarwal, M.D. resigned from his position as Executive Vice President, Head of Development, and Chief Medical Officer of the Company, effective as of April 10, 2023.
Douglas E. Williams, Ph.D., has been appointed and will join the Company as Executive Vice President and President, Research and Development, effective April 10, 2023.
On September 1, 2021, Geoffrey von Maltzahn, Ph.D. notified Sana Biotechnology, Inc. (“Sana”) of his decision to resign from the Board of Directors of Sana (the “Board”), effective immediately.
Max materiality 0.85 · Median 0.60 · Most common event other_material